AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 766062 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (2 mg)
Number of subjects: 0
Study 766062 — intervention group
Group type: COMPARATOR
Intervention: Pro‐Banthine (45 mg)
Number of subjects: 0
Study 31280348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bortezomib (1.6 mg/m2) with dexamethasone and cyclophosphamide
Number of subjects: 85
Study 31280348 — intervention group
Group type: COMPARATOR
Intervention: Low-dose bortezomib (1.3 mg/m2) with dexamethasone and cyclophosphamide
Number of subjects: 85
Study 31280348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bortezomib (1.6 mg/m2)
Number of subjects: 85
Study 31280348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bortezomib (1.6 mg/m2) and low-dose bortezomib (1.3 mg/m2)
Number of subjects: 85
Study 28327447 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interview Group (MIG)
Number of subjects: 83
Study 28327447 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intervention Group (CIG)
Number of subjects: 83
Study 28327447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 25349943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises (PMEs) with instruction and feedback
Number of subjects: 250
Study 25349943 — intervention group
Group type: COMPARATOR
Intervention: Prior instruction
Number of subjects: 250
Study 25349943 — intervention group
Group type: COMPARATOR
Intervention: Prior feedback
Number of subjects: 250
Study 25349943 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction 'Squeeze the vaginal muscles you use to hold your urine'
Number of subjects: 250
Study 22935739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 12
Study 22935739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT) with placebo
Number of subjects: 12
Study 22935739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT) with caffeine (3 mg·kg(‐1))
Number of subjects: 12
Study 22935739 — intervention group
Group type: COMPARATOR
Intervention: Resting with caffeine (3 mg·kg(‐1))
Number of subjects: 12
Study 21450707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral insertion of 0.20×15 mm Seirin needles to 12 mm depth at ST36, daily treatments of 30 s duration for three consecutive workdays
Number of subjects: 0
Study 21450707 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 19661447 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 8
Study 17900887 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (S 50 mcg/FP 250 mcg b.i.d.)
Number of subjects: 35
Study 17900887 — intervention group
Group type: EXPERIMENTAL
Intervention: S+FP (S 50 mcg b.i.d.+FP 250 mcg b.i.d.)
Number of subjects: 35
Study 17900887 — intervention group
Group type: COMPARATOR
Intervention: S+FP
Number of subjects: 35
Study 17900887 — intervention group
Group type: COMPARATOR
Intervention: SFC
Number of subjects: 35
Study 15144296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 300 microg
Number of subjects: 40
Study 15144296 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 40
Study 11985192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealants with resin-modified glass ionomer - Vitremer (n=29)
Number of subjects: 250
Study 11985192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish - Duraphat (n=36)
Number of subjects: 250
Study 11985192 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing and 0.2% NaF weekly mouthwashes (Control group, n=33)
Number of subjects: 250
Study 9377658 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotrienes B4 and C4 levels in cerebrospinal fluid (CSF) of patients with multiple sclerosis
Number of subjects: 47
Study 9377658 — intervention group
Group type: COMPARATOR
Intervention: Leukotrienes B4 and C4 levels in patients with atherosclerotic dementia
Number of subjects: 47
Study 9377658 — intervention group
Group type: COMPARATOR
Intervention: Leukotrienes B4 and C4 levels in patients with headache
Number of subjects: 47
Study 8197861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coating
Number of subjects: 0
Study 8197861 — intervention group
Group type: COMPARATOR
Intervention: Cement fixation
Number of subjects: 0
Study 3390674 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery to the communicating veins and elastic stockings
Number of subjects: 41
Study 3390674 — intervention group
Group type: COMPARATOR
Intervention: Elastic stockings only
Number of subjects: 41
Study 3390674 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and elastic stockings in limbs without post-thrombotic changes
Number of subjects: 41
Study 3390674 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and elastic stockings in limbs with post-thrombotic changes
Number of subjects: 41
Study 29926752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31072314 — intervention group
Group type: EXPERIMENTAL
Intervention: Kypho-IORT (Kyphoplasty plus IORT with 8 Gy prescribed to 13 mm depth)
Number of subjects: 54
Study 31072314 — intervention group
Group type: COMPARATOR
Intervention: EBRT (External Beam Radiotherapy) with either 30 Gy in 10 fractions or 8 Gy as a single dose
Number of subjects: 54
Study 31072314 — intervention group
Group type: EXPERIMENTAL
Intervention: Kypho-IORT
Number of subjects: 54
Study 31072314 — intervention group
Group type: COMPARATOR
Intervention: Kypho-IORT and EBRT
Number of subjects: 54
Study 27503746 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional needle acupuncture
Number of subjects: 116
Study 26761967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil in addition to standard therapy (aspirin, rosuvastatin, valsartan, bisoprolol)
Number of subjects: 0
Study 26761967 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (aspirin, rosuvastatin, valsartan, bisoprolol)
Number of subjects: 0
Study 26761967 — intervention group
Group type: COMPARATOR
Intervention: Long-acting form of nitrates
Number of subjects: 0
Study 23317561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meprednisone preoperatively
Number of subjects: 54
Study 23317561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative systemic steroids)
Number of subjects: 54
Study 22021510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT examination
Number of subjects: 26724
Study 22021510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT examination (using ICRP 60 tissue-weighting factors)
Number of subjects: 26724
Study 22021510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT examination (using ICRP 103 tissue-weighting factors)
Number of subjects: 26724
Study 18835927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (6-week administration)
Number of subjects: 18
Study 18835927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to fluoxetine)
Number of subjects: 18
Study 17973988 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise prior to fat ingestion
Number of subjects: 8
Study 17973988 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal alone (control)
Number of subjects: 8
Study 17973988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled exercise and control data
Number of subjects: 8
Study 15072173 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating CPAP (APAP)
Number of subjects: 10
Study 15072173 — intervention group
Group type: COMPARATOR
Intervention: Fixed CPAP (F-CPAP)
Number of subjects: 10
Study 15072173 — intervention group
Group type: COMPARATOR
Intervention: F-CPAP
Number of subjects: 10
Study 15072173 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 10
Study 11278212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose step-up regimen (starting dose 75 IU)
Number of subjects: 26
Study 11278212 — intervention group
Group type: COMPARATOR
Intervention: Modified step-down regimen (starting dose 300 IU, followed by 3 days free of treatment, then 75 IU daily)
Number of subjects: 26
Study 9042530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim Light‐Caffeine (200 mg twice each night)
Number of subjects: 0
Study 9042530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light‐Caffeine (> or = 2000 lux)
Number of subjects: 0
Study 9042530 — intervention group
Group type: COMPARATOR
Intervention: Dim Light‐Placebo
Number of subjects: 0
Study 9042530 — intervention group
Group type: COMPARATOR
Intervention: Bright Light‐Placebo
Number of subjects: 0
Study 7943687 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic beta-activity at the vertex lead
Number of subjects: 31
Study 7943687 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger amplitude carotid pulse
Number of subjects: 31
Study 3652755 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Graphics Corporation System 2000
Number of subjects: 12
Study 3652755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensormedics MMC Horizon system
Number of subjects: 12
Study 3652755 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods of analyzing data
Number of subjects: 12
Study 31461478 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term meditators (LTM)
Number of subjects: 99
Study 31461478 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction (MNP intervention)
Number of subjects: 99
Study 31461478 — intervention group
Group type: COMPARATOR
Intervention: Health enhancement program (MNP intervention)
Number of subjects: 99
Study 31461478 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (MNP intervention)
Number of subjects: 99
Study 27651510 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated high-volume morphine-ADER-IMT (60 mg)
Number of subjects: 46
Study 27651510 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated low-volume morphine-ADER-IMT (60 mg)
Number of subjects: 46
Study 27651510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact oral morphine-ADER-IMT (60 mg)
Number of subjects: 46
Study 27651510 — intervention group
Group type: COMPARATOR
Intervention: Manipulated low-volume morphine ER (60 mg)
Number of subjects: 46
Study 27655459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education (3 messages: bedtime before 21:00; no caffeine; keep electronics out of the bedroom)
Number of subjects: 152
Study 27655459 — intervention group
Group type: COMPARATOR
Intervention: Control (dental hygiene education)
Number of subjects: 152
Study 22740112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 211
Study 22740112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 21993207 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 74
Study 21993207 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 74
Study 19436225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% DHEA
Number of subjects: 216
Study 19436225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% DHEA
Number of subjects: 216
Study 19436225 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% DHEA
Number of subjects: 216
Study 17589628 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Number of subjects: 483
Study 17589628 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 483
Study 17589628 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 483
Study 14987957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention, 10 weeks
Number of subjects: 29
Study 14987957 — intervention group
Group type: COMPARATOR
Intervention: Comparison experience
Number of subjects: 29
Study 11342682 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine (150 mg/day)
Number of subjects: 25
Study 11342682 — intervention group
Group type: EXPERIMENTAL
Intervention: carbamazepine (mean 696 mg/day)
Number of subjects: 25
Study 11342682 — intervention group
Group type: COMPARATOR
Intervention: nondrug average
Number of subjects: 25
Study 11342682 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 25
Study 9683389 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fat products
Number of subjects: 241
Study 9683389 — intervention group
Group type: COMPARATOR
Intervention: Full fat products
Number of subjects: 241
Study 8149032 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 milligrams per kilogram per minute of glucose infusion during preoperative overnight fasting
Number of subjects: 12
Study 8149032 — intervention group
Group type: COMPARATOR
Intervention: No infusion (control group) during preoperative overnight fasting
Number of subjects: 12
Study 2980998 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneoscopy with directed liver biopsy
Number of subjects: 23
Study 2980998 — intervention group
Group type: COMPARATOR
Intervention: Blind percutaneous liver biopsy
Number of subjects: 23
Study 31385712 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational valence
Number of subjects: 112
Study 31385712 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational valence with popular conversation partner
Number of subjects: 112
Study 31209507 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 30
Study 31209507 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 30
Study 31209507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28173786 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 124
Study 28173786 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Support
Number of subjects: 124
Study 28173786 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 124
Study 25782429 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 200
Study 25782429 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fruit consumption
Number of subjects: 200
Study 25782429 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride application
Number of subjects: 200
Study 25782429 — intervention group
Group type: COMPARATOR
Intervention: Nonvegetarians
Number of subjects: 200
Study 23996803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol per day for 3 months
Number of subjects: 35
Study 21873902 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups with feet elevated on a 30.48-cm box
Number of subjects: 23
Study 21873902 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups with hands elevated on a 30.48-cm box
Number of subjects: 23
Study 21873902 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups from the flexed knee position
Number of subjects: 23
Study 21873902 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups with hands elevated on a 60.96-cm box
Number of subjects: 23
Study 19470837 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pramlintide
Number of subjects: 266
Study 19470837 — intervention group
Group type: COMPARATOR
Intervention: Placebo pramlintide
Number of subjects: 266
Study 17878479 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg plus docetaxel
Number of subjects: 127
Study 17878479 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg plus docetaxel
Number of subjects: 127
Study 17878479 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 127
Study 15135147 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (1500 mg daily for 12 weeks)
Number of subjects: 19
Study 15135147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1500 mg daily for 12 weeks)
Number of subjects: 19
Study 15135147 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 19
Study 15135147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15135147 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate and Placebo
Number of subjects: 19
Study 10690829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin‐C (0.3 mg/ml) applied under both flaps (group 3)
Number of subjects: 68
Study 10690829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the scleral flap (group 2)
Number of subjects: 68
Study 10690829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the conjunctival flap (group 1)
Number of subjects: 68
Study 9368726 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous chemotherapy with radiotherapy
Number of subjects: 19
Study 8461475 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 128
Study 8461475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 3771854 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin in combination with 0.5% minoxidil
Number of subjects: 56
Study 3771854 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin alone
Number of subjects: 56
Study 29980818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis decoction (200 ml)
Number of subjects: 13
Study 29980818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis oil (1 ml)
Number of subjects: 13
Study 29980818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis decoction and cannabis oil
Number of subjects: 13
Study 27720409 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall conditions (two retention intervals: short and long; four prompts: forward, meal name, open, and reverse)
Number of subjects: 455
Study 24996447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) administered one pill a day for 63 days
Number of subjects: 156
Study 24996447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) plus Dan'e mixture (30 g/day for 30 days)
Number of subjects: 156
Study 24996447 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy alone (Control Group C)
Number of subjects: 156
Study 22799753 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment administered twice daily for 52 weeks
Number of subjects: 504
Study 22799753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 504
Study 20141396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 56
Study 20141396 — intervention group
Group type: COMPARATOR
Intervention: Citalopram/Escitalopram
Number of subjects: 56
Study 20141396 — intervention group
Group type: COMPARATOR
Intervention: No antidepressant
Number of subjects: 56
Study 18031326 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 1 mg/m²/day for 12 months
Number of subjects: 43
Study 18031326 — intervention group
Group type: COMPARATOR
Intervention: Non-GH treated control group
Number of subjects: 43
Study 15695835 — intervention group
Group type: EXPERIMENTAL
Intervention: Periwound cleansing using a skin cleanser
Number of subjects: 17
Study 14508234 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 32
Study 14508234 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 32
Study 10834421 — intervention group
Group type: EXPERIMENTAL
Intervention: lispro high mixture (HM)
Number of subjects: 35
Study 10834421 — intervention group
Group type: COMPARATOR
Intervention: human regular insulin therapy
Number of subjects: 35
Study 8807200 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp120 HIV-1 vaccine
Number of subjects: 25
Study 8807200 — intervention group
Group type: EXPERIMENTAL
Intervention: IIIB rgp120 HIV-1 vaccine
Number of subjects: 25
Study 8807200 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming immunization with IIIB rgp120 followed by booster injections of MN rgp120
Number of subjects: 25
Study 8807200 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp120 HIV-1 vaccine given alone
Number of subjects: 25
Study 8807200 — intervention group
Group type: COMPARATOR
Intervention: HIV-1IIIB-based gp160 vaccines
Number of subjects: 25
Study 1555315 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (no intervention mentioned)
Number of subjects: 40
Study 4029016 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 250 mg/h
Number of subjects: 5
Study 4029016 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 750 mg/h
Number of subjects: 5
Study 4029016 — intervention group
Group type: COMPARATOR
Intervention: Probenecid (blocking tubular excretion)
Number of subjects: 5
Study 29058272 — intervention group
Group type: EXPERIMENTAL
Intervention: Health blog
Number of subjects: 0
Study 29058272 — intervention group
Group type: COMPARATOR
Intervention: Control blog
Number of subjects: 0
Study 28353022 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% morphine
Number of subjects: 45
Study 28353022 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% morphine
Number of subjects: 45
Study 28353022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 28353022 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (0.2% morphine, 0.4% morphine, placebo)
Number of subjects: 45
Study 28353022 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 26221049 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 32
Study 26221049 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 32
Study 24645871 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term integrative body-mind training (IBMT) for 30 min per day for 7 days
Number of subjects: 40
Study 24645871 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (RT)
Number of subjects: 40
Study 22456699 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual practice dysphagia therapy
Number of subjects: 759
Study 22456699 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey responses from SLPs
Number of subjects: 759
Study 19843655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine (8 to 32 mg daily for 14 to 600 days)
Number of subjects: 156
Study 19843655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine in nonsmoking African Americans
Number of subjects: 156